Table 3.

Therapeutic algorithm

Patients with clear cell renal carcinoma		First-line therapy	Second-line therapy
Without previous treatment	Prognostic grade: favorable or intermediate prognosis	Sunitinib or	IL-2 high dose or
		Bevacizumab + interferon α	clinical trial
	Prognostic grade: poor	Temsirolimus	Sunitinib or
			clinical trial
With previous treatment	With cytokine	Sorafenib	Sunitinib
	With multitargeted therapy	Everolimus	Tyrosine kinase inhibitor or clinical trial
Patients with not clear cell renal carcinoma		Temsirolimus	Sunitinib or
			sorafenib